UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Cytoreductive nephrectomy in the current treatment algorithm

Kuusk, T; Szabados, B; Liu, WK; Powles, T; Bex, A; (2019) Cytoreductive nephrectomy in the current treatment algorithm. Therapeutic Advances in Medical Oncology , 11 pp. 1-7. 10.1177/1758835919879026. Green open access

[thumbnail of Bex 1758835919879026.pdf]
Preview
Text
Bex 1758835919879026.pdf - Published version

Download (200kB) | Preview

Abstract

The two recent prospective randomized trials CARMENA and SURTIME have changed the therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to investigate whether cytoreductive nephrectomy (CN) is required in the targeted therapy area, whereas SURTIME studied whether deferred CN in combination with sunitinib can be used to identify patients with inherent targeted therapy resistance. In the current review, we provide a comprehensive discussion of two randomized studies and the current evidence with up-do-date algorithms for treating primary metastatic clear-cell renal cell carcinoma in the era of targeted therapy and immune-checkpoint inhibition.

Type: Article
Title: Cytoreductive nephrectomy in the current treatment algorithm
Open access status: An open access version is available from UCL Discovery
DOI: 10.1177/1758835919879026
Publisher version: https://doi.org/10.1177/1758835919879026
Language: English
Additional information: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords: Science & Technology, Life Sciences & Biomedicine, Oncology, cytoreductive nephrectomy, immunotherapy, metastatic renal cell carcinoma, renal cell carcinoma, sunitinib, systemic therapy, targeted therapy, tyrosine kinase inhibitors, RENAL-CELL CARCINOMA, TARGETED THERAPY, INTERFERON-ALPHA, SURVIVAL, SUNITINIB, CANCER, MODEL
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci > Department of Surgical Biotechnology
URI: https://discovery.ucl.ac.uk/id/eprint/10085827
Downloads since deposit
20Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item